Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Depression can damage your memory
Once they enter memory, depressive thoughts can linger for long in affected people, and this extended duration may reduce the amount of information that these individuals can remember, suggests new research.

[adsense:336x280:8701650588]
- Read more about Hepatitis A virus likely of animal origin
Like HIV and Ebola, the hepatitis A virus is of likely animal origin, finds a large-scale study looking into the evolutionary origins of the global pathogen.
- Read more about Even 'SAFE' levels of air pollution up heart attack risk
Particulate matter and nitric dioxide emissions from industrial plants or vehicles increase the risk of heart attacks, despite being within 'safe' levels of air pollution, a new study has claimed. The study examined the effect of short term exposure to air pollution on the risk of ST-segment elevation myocardial infarction (STEMI). This type of myocardial infarction (heart attack) has the worst prognosis and is caused by thrombotic occlusion of a coronary artery that damages the heart.
- Read more about ViiV Healthcare declare positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) were comparable in maintaining viral suppression rates to a three drug oral regimen of investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs). The 32 week results of LATTE 2 will be presented at a forthcoming scientific conference. ViiV Healthcare and Janssen Sciences Ireland UC (Janssen) are collaborating to conduct LATTE 2.
- Read more about Merck Serono and Selvita to discover new drugs for cancer metabolism
Merck Serono has signed a collaboration with Polish biotechnology firm Selvita to jointly discover small molecule based drugs targeting proteins involved in cancer cell metabolism.
- Read more about GSK, Merck to study immunotherapy combination as potential cancer treatment
GSK and Merck, known as MSD outside the US and Canada, announced the initiation of a phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment.
- Read more about Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Collaborate as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program
Bristol-Myers Squibb Company (NYSE:BMY) announced that they have entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
- Read more about Mylan receive U.S. FTC Approval For Proposed Acquisition Of Perrigo
Mylan N.V. (NASDAQ: MYL) announced the U.S. Federal Trade Commission ("FTC") has cleared the company's proposed transaction to acquire Perrigo Company plc (NYSE: PRGO; TASE) subject to Mylan's divestiture of certain products following the consummation of the offer. The FTC clearance represents the final regulatory clearance needed by Mylan to close its acquisition of Perrigo and represents the last remaining condition that needs to be satisfied for the successful completion of the offer other than the acceptance condition.
- Read more about European Commission Approves Bayer Flupyradifurone
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto Prime in Europe. Its active ingredient flupyradifurone, which belongs to the chemical class of butenolides, has been approved for the maximum time span of 10 years by the European Commission in accordance with Regulation (EC) 1107/2009. The first national registrations of Sivanto prime in European countries are expected in 2016 and the market introduction is planned for 2017.
- Read more about Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound
Boehringer Ingelheim announced at the BIO-Europe® conference in Munich, Germany, the initiation of a global Phase II trial evaluating the efficacy and safety of BI 1482694 (HM61713) in patients with T790M mutation-positive non-small cell lung cancer (NSCLC), whose tumours stopped responding to currently available epidermal growth factor receptor (EGFR) directed therapies. The primary endpoint of this trial, which is the first in a broad clinical development programme for BI 1482694, is objective response rate (ORR).

[adsense:336x280:8701650588]